Skip to main content
Clinical Trials/NCT01528007
NCT01528007CompletedPhase 4

Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention - a Placebo Controlled Trial

Finnish Institute for Health and Welfare1 site in 1 country100 target enrollmentStarted: January 2011Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
100
Locations
1
Primary Endpoint
PG-YBOCS.

Study Overview

Brief Summary

The aim of this research is to explore the efficacy of the opiate antagonist, naltrexone as combined with CBT-intervention in the treatment of pathological gambling (PG). The study period is 2011-2014 during which one hundred Pathological Gamblers will be recruited to participate to this placebo-controlled double-blind trial.

Detailed Description

All participants have to be able to read and understand the patient information sheet and sign the informed consent. All participants are free to stop being in the study whenever they wanted. The patients are not paid or reimbursed for participation.

The study periods is 21 weeks during which the participant's have 8 appointments with the researchers. During the meetings research data will be collected and the participant is having Controlled Behavioral Therapy (CBT) consulting from a trained therapist. At the study visits, the subjects are given written instructions for the proper use of naltrexone and advised to take 50 mg naltrexone approximately one hour before gambling or feeling urges to gamble (and to refrain from taking naltrexone at other times). In this study the maximal daily dose is 50mg of naltrexone. The medication is free for the subjects.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • pathological gambling (scores 5+ from SOGS-R and DSM-IV criteria)

Exclusion Criteria

  • acute hepatitis
  • severe liver or kidney dysfunction
  • suicide risk or severe depression or other untreated mental health problem
  • participation to other gambling research at the same time
  • the use of drugs (especially opiates)
  • pregnancy
  • prisoners
  • retarded and mentally ill patients were also excluded

Arms & Interventions

Placebo pill.

Placebo Comparator

Intervention: Placebo (Drug)

50mg Naltrexone when needed

Active Comparator

Intervention: Naltrexone pharmacotherapy (Drug)

Outcomes

Primary Outcomes

PG-YBOCS.

Time Frame: Up to 21 weeks.

The investigators will interview PG-YBOCS questionnaire from the participants.

Secondary Outcomes

  • Alcohol use.(Up to 21 weeks.)
  • Quality of life.(Up to 21 weeks.)

Investigators

Sponsor
Finnish Institute for Health and Welfare
Sponsor Class
Other Gov
Responsible Party
Principal Investigator
Principal Investigator

Hannu Alho

Professor

Finnish Institute for Health and Welfare

Study Sites (1)

Loading locations...

Similar Trials

Treatment of Pathological Gambling With... | Clinical Trial